485 related articles for article (PubMed ID: 29121974)
1. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol.
Qurashi I; Chaudhry IB; Khoso AB; Farooque S; Lane S; Husain MO; Chu S; Sarginson J; Hamarani M; Naqvi HA; Razzaque B; Minhas FA; Yung AR; Deakin JFW; Husain N
Trials; 2017 Nov; 18(1):524. PubMed ID: 29121974
[TBL] [Abstract][Full Text] [Related]
2. A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study.
Qurashi I; Chaudhry IB; Khoso AB; Omair Husain M; Hafeez D; Kiran T; Lane S; Naqvi HA; Minhas FA; Tamizuddin Nizami A; Razzaque B; Qambar Bokhari S; Yung AR; Deakin B; Husain N
Brain Behav Immun; 2024 Jan; 115():609-616. PubMed ID: 37924960
[TBL] [Abstract][Full Text] [Related]
3. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.
Amminger GP; Schäfer MR; Papageorgiou K; Klier CM; Cotton SM; Harrigan SM; Mackinnon A; McGorry PD; Berger GE
Arch Gen Psychiatry; 2010 Feb; 67(2):146-54. PubMed ID: 20124114
[TBL] [Abstract][Full Text] [Related]
4. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.
Markulev C; McGorry PD; Nelson B; Yuen HP; Schaefer M; Yung AR; Thompson A; Berger G; Mossaheb N; Schlögelhofer M; Smesny S; de Haan L; Riecher-Rössler A; Nordentoft M; Chen EYH; Verma S; Hickie I; Amminger GP
Early Interv Psychiatry; 2017 Oct; 11(5):418-428. PubMed ID: 26279065
[TBL] [Abstract][Full Text] [Related]
5. Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11DS genetically at high risk for psychosis. Protocol of a randomized, double-blind, placebo-controlled treatment trial.
Armando M; De Crescenzo F; Vicari S; Digilio MC; Pontillo M; Papaleo F; Amminger GP
Early Interv Psychiatry; 2016 Oct; 10(5):390-6. PubMed ID: 25345540
[TBL] [Abstract][Full Text] [Related]
6. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.
McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EY; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Amminger GP
JAMA Psychiatry; 2017 Jan; 74(1):19-27. PubMed ID: 27893018
[TBL] [Abstract][Full Text] [Related]
7. The synchronized trial on expectant mothers with depressive symptoms by omega-3 PUFAs (SYNCHRO): Study protocol for a randomized controlled trial.
Nishi D; Su KP; Usuda K; Chiang YJ; Guu TW; Hamazaki K; Nakaya N; Sone T; Sano Y; Tachibana Y; Ito H; Isaka K; Hashimoto K; Hamazaki T; Matsuoka YJ
BMC Psychiatry; 2016 Sep; 16(1):321. PubMed ID: 27630014
[TBL] [Abstract][Full Text] [Related]
8. A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial.
Chaudhry IB; Husain N; ur Rahman R; Husain MO; Hamirani MM; Kazmi A; Baig S; Haddad PM; Buch MH; Qureshi I; Mehmood N; Kiran T; Fu B; Afsar S; Deakin B
Trials; 2015 Jan; 16():9. PubMed ID: 25563714
[TBL] [Abstract][Full Text] [Related]
9. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment.
Chaudhry IB; Hallak J; Husain N; Minhas F; Stirling J; Richardson P; Dursun S; Dunn G; Deakin B
J Psychopharmacol; 2012 Sep; 26(9):1185-93. PubMed ID: 22526685
[TBL] [Abstract][Full Text] [Related]
10. Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?
Mossaheb N; Schäfer MR; Schlögelhofer M; Klier CM; Cotton SM; McGorry PD; Amminger GP
Schizophr Res; 2013 Aug; 148(1-3):163-7. PubMed ID: 23778032
[TBL] [Abstract][Full Text] [Related]
11. Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial.
Husain MI; Chaudhry IB; Rahman RR; Hamirani MM; Qurashi I; Khoso AB; Deakin JF; Husain N; Young AH
Trials; 2015 Sep; 16():410. PubMed ID: 26374703
[TBL] [Abstract][Full Text] [Related]
12. Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis - Results of the randomized controlled Vienna omega-3 study.
Smesny S; Milleit B; Schaefer MR; Hesse J; Schlögelhofer M; Langbein K; Hipler UC; Berger M; Cotter DR; Sauer H; McGorry PD; Amminger GP
Schizophr Res; 2017 Oct; 188():110-117. PubMed ID: 28126360
[TBL] [Abstract][Full Text] [Related]
13. Frontal delta power associated with negative symptoms in ultra-high risk individuals who transitioned to psychosis.
Lavoie S; Schäfer MR; Whitford TJ; Benninger F; Feucht M; Klier CM; Yuen HP; Pantelis C; McGorry PD; Amminger GP
Schizophr Res; 2012 Jul; 138(2-3):206-11. PubMed ID: 22520856
[TBL] [Abstract][Full Text] [Related]
14. The Beyond Ageing Project Phase 2--a double-blind, selective prevention, randomised, placebo-controlled trial of omega-3 fatty acids and sertraline in an older age cohort at risk for depression: study protocol for a randomized controlled trial.
Cockayne NL; Duffy SL; Bonomally R; English A; Amminger PG; Mackinnon A; Christensen HM; Naismith SL; Hickie IB
Trials; 2015 Jun; 16():247. PubMed ID: 26037484
[TBL] [Abstract][Full Text] [Related]
15. Differences in omega-3 and omega-6 polyunsaturated fatty acid consumption in people at ultra-high risk of psychosis, first-episode schizophrenia, and in healthy controls.
Pawełczyk T; Trafalska E; Pawełczyk A; Kotlicka-Antczak M
Early Interv Psychiatry; 2017 Dec; 11(6):498-508. PubMed ID: 26279283
[TBL] [Abstract][Full Text] [Related]
16. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids.
Amminger GP; Mechelli A; Rice S; Kim SW; Klier CM; McNamara RK; Berk M; McGorry PD; Schäfer MR
Transl Psychiatry; 2015 Jan; 5(1):e495. PubMed ID: 25585167
[TBL] [Abstract][Full Text] [Related]
17. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial.
Andrieu S; Guyonnet S; Coley N; Cantet C; Bonnefoy M; Bordes S; Bories L; Cufi MN; Dantoine T; Dartigues JF; Desclaux F; Gabelle A; Gasnier Y; Pesce A; Sudres K; Touchon J; Robert P; Rouaud O; Legrand P; Payoux P; Caubere JP; Weiner M; Carrié I; Ousset PJ; Vellas B;
Lancet Neurol; 2017 May; 16(5):377-389. PubMed ID: 28359749
[TBL] [Abstract][Full Text] [Related]
18. A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial.
Rietdijk J; Dragt S; Klaassen R; Ising H; Nieman D; Wunderink L; Delespaul P; Cuijpers P; Linszen D; van der Gaag M
Trials; 2010 Mar; 11():30. PubMed ID: 20307268
[TBL] [Abstract][Full Text] [Related]
19. Effects of omega-3 polyunsaturated fatty acid supplementation in patients with chronic chagasic cardiomyopathy: study protocol for a randomized controlled trial.
Silva PS; Sperandio da Silva GM; de Souza AP; Cardoso CS; Fonseca CA; Brito PD; Saraiva RM; Brasil PE; Pinheiro RO; Hasslocher-Moreno AM; Xavier SS; Sousa AS
Trials; 2013 Nov; 14():379. PubMed ID: 24216069
[TBL] [Abstract][Full Text] [Related]
20. [Membrane lipids in schizophrenia and early phases of psychosis: Potential biomarkers and therapeutic targets?].
Frajerman A; Kebir O; Chaumette B; Tessier C; Lamazière A; Nuss P; Krebs MO
Encephale; 2020 Jun; 46(3):209-216. PubMed ID: 32151446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
